Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.
We've helped large and small companies and governments around with world with projects such as:
After years of maintaining DrugPatentWatch as a comprehesive analytics platform, we're making a distillation of cutting-edge information available to you as a daily newsletter.
DrugPatentWatch has been publishing critical business intelligence since 2002, so we've learned what matters to you.
We've served hundreds of clients in more than 70 countries, including investment banks, big/small drug companies, payers, governments, and more…
It is from serving these diverse needs that the Daily Briefing was born.
The purpose of the Daily Briefing is to arm you with objective information so you can gain deep insights into gaps in the market and how they can be exploited.
In addition to our daily updates of patent expirations and other market-changing events, the Daily Briefing includes articles on topics like:
Readers outside the United States are covered as well.
The Daily Briefing leverages the robust DrugPatentWatch Business intelligence platform, which includes patent coverage in 134 countries.
In a single click you can see the international equivalents of each expired patent.
We track inbound searches to DrugPatentWatch to help you stay on top of what's moving markets.
Find out what drugs, which companies, and what other content is most popular with our global audience, right now!
No need to worry about missed issues.
The Daily Briefing is sent daily, direct to your inbox.
If you want to get caught up on prior Daily Briefings, we have back issues available at your disposal.
We plan on increasing the subscription price as we expand our team and invest more into the Daily Briefing.
But, if you subscribe now you can lock in the low introductory rates.
And to make sure you’re happy we offer a free trial.